

Young Suk Park

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1806086/publications.pdf>

Version: 2024-02-01

181
papers

4,636
citations

185998

28
h-index

123241

61
g-index

183
all docs

183
docs citations

183
times ranked

8274
citing authors

#	ARTICLE	IF	CITATIONS
1	Comprehensive molecular characterization of clinical responses to PD-1 inhibition in metastatic gastric cancer. <i>Nature Medicine</i> , 2018, 24, 1449-1458.	15.2	1,071
2	Phase III Trial to Compare Adjuvant Chemotherapy With Capecitabine and Cisplatin Versus Concurrent Chemoradiotherapy in Gastric Cancer: Final Report of the Adjuvant Chemoradiotherapy in Stomach Tumors Trial, Including Survival and Subset Analyses. <i>Journal of Clinical Oncology</i> , 2015, 33, 3130-3136.	0.8	370
3	Oxaliplatin, fluorouracil, and leucovorin versus fluorouracil and leucovorin as adjuvant chemotherapy for locally advanced rectal cancer after preoperative chemoradiotherapy (ADORE): an open-label, multicentre, phase 2, randomised controlled trial. <i>Lancet Oncology</i> , The, 2014, 15, 1245-1253.	5.1	336
4	Tumor Genomic Profiling Guides Patients with Metastatic Gastric Cancer to Targeted Treatment: The VIKTORY Umbrella Trial. <i>Cancer Discovery</i> , 2019, 9, 1388-1405.	7.7	155
5	Modified XELIRI (capecitabine plus irinotecan) versus FOLFIRI (leucovorin, fluorouracil, and) Tj ETQq1 1 0.784314 rgBT /Overlock 10 T 5 colorectal cancer (AXEPT): a multicentre, open-label, randomised, non-inferiority, phase 3 trial. <i>Lancet Oncology</i> , The, 2018, 19, 660-671.	5.1	107
6	Oxaliplatin-Based Adjuvant Chemotherapy for Rectal Cancer After Preoperative Chemoradiotherapy (ADORE): Long-Term Results of a Randomized Controlled Trial. <i>Journal of Clinical Oncology</i> , 2019, 37, 3111-3123.	0.8	100
7	Prospective blinded study of somatic mutation detection in cell-free DNA utilizing a targeted 54-gene next generation sequencing panel in metastatic solid tumor patients. <i>Oncotarget</i> , 2015, 6, 40360-40369.	0.8	85
8	Simvastatin plus capecitabine+ cisplatin versus placebo plus capecitabine+ cisplatin in patients with previously untreated advanced gastric cancer: A double-blind randomised phase 3 study. <i>European Journal of Cancer</i> , 2014, 50, 2822-2830.	1.3	79
9	c-MET Overexpression in Colorectal Cancer: A Poor Prognostic Factor for Survival. <i>Clinical Colorectal Cancer</i> , 2018, 17, 165-169.	1.0	71
10	Correlating programmed death ligand 1 (PD-L1) expression, mismatch repair deficiency, and outcomes across tumor types: implications for immunotherapy. <i>Oncotarget</i> , 2017, 8, 77415-77423.	0.8	68
11	A Phase 1 Study of LY2874455, an Oral Selective pan-FGFR Inhibitor, in Patients with Advanced Cancer. <i>Targeted Oncology</i> , 2017, 12, 463-474.	1.7	64
12	Gastrointestinal malignancies harbor actionable MET exon 14 deletions. <i>Oncotarget</i> , 2015, 6, 28211-28222.	0.8	57
13	Genomic characterization of intrinsic and acquired resistance to cetuximab in colorectal cancer patients. <i>Scientific Reports</i> , 2019, 9, 15365.	1.6	54
14	Phase I Study of Ceralasertib (AZD6738), a Novel DNA Damage Repair Agent, in Combination with Weekly Paclitaxel in Refractory Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 4700-4709.	3.2	54
15	NTRK1 rearrangement in colorectal cancer patients: evidence for actionable target using patient-derived tumor cell line. <i>Oncotarget</i> , 2015, 6, 39028-39035.	0.8	53
16	Patient-derived cell models as preclinical tools for genome-directed targeted therapy. <i>Oncotarget</i> , 2015, 6, 25619-25630.	0.8	48
17	MCT4 as a potential therapeutic target for metastatic gastric cancer with peritoneal carcinomatosis. <i>Oncotarget</i> , 2016, 7, 43492-43503.	0.8	45
18	Metformin enhances the response to radiotherapy in diabetic patients with rectal cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , 2016, 142, 1377-1385.	1.2	40

#	ARTICLE	IF	CITATIONS
19	A multi-center, open-label, randomized phase III trial of first-line chemotherapy with capecitabine monotherapy versus capecitabine plus oxaliplatin in elderly patients with advanced gastric cancer. <i>Journal of Geriatric Oncology</i> , 2017, 8, 170-175.	0.5	39
20	Anastomotic Leak Does Not Impact Oncologic Outcomes After Preoperative Chemoradiotherapy and Resection for Rectal Cancer. <i>Annals of Surgery</i> , 2019, 269, 678-685.	2.1	37
21	MCT4 Expression Is a Potential Therapeutic Target in Colorectal Cancer with Peritoneal Carcinomatosis. <i>Molecular Cancer Therapeutics</i> , 2018, 17, 838-848.	1.9	36
22	Identification of the BRAF V600E mutation in gastroenteropancreatic neuroendocrine tumors. <i>Oncotarget</i> , 2016, 7, 4024-4035.	0.8	36
23	The impact of KRAS mutations on prognosis in surgically resected colorectal cancer patients with liver and lung metastases: a retrospective analysis. <i>BMC Cancer</i> , 2016, 16, 120.	1.1	35
24	Pazopanib, a Novel Multitargeted Kinase Inhibitor, Shows Potent <i>In Vitro</i> Antitumor Activity in Gastric Cancer Cell Lines with FGFR2 Amplification. <i>Molecular Cancer Therapeutics</i> , 2014, 13, 2527-2536.	1.9	34
25	The Influence of Metastatic Lymph Node Ratio on the Treatment Outcomes in the Adjuvant Chemoradiotherapy in Stomach Tumors (ARTIST) Trial: A Phase III Trial. <i>Journal of Gastric Cancer</i> , 2016, 16, 105.	0.9	34
26	Large-scale clinical validation of biomarkers for pancreatic cancer using a mass spectrometry-based proteomics approach. <i>Oncotarget</i> , 2017, 8, 42761-42771.	0.8	34
27	Tissue recommendations for precision cancer therapy using next generation sequencing: a comprehensive single cancer center's experiences. <i>Oncotarget</i> , 2017, 8, 42478-42486.	0.8	32
28	Detection of novel and potentially actionable anaplastic lymphoma kinase (ALK) rearrangement in colorectal adenocarcinoma by immunohistochemistry screening. <i>Oncotarget</i> , 2015, 6, 24320-24332.	0.8	32
29	Effects of adjuvant radiotherapy on completely resected gastric cancer: A radiation oncologist's view of the ARTIST randomized phase III trial. <i>Radiotherapy and Oncology</i> , 2015, 117, 171-177.	0.3	31
30	Prospective Feasibility Study for Using Cell-Free Circulating Tumor DNA-Guided Therapy in Refractory Metastatic Solid Cancers: An Interim Analysis. <i>JCO Precision Oncology</i> , 2017, 1, 1-15.	1.5	31
31	Claudin 18.2 expression in various tumor types and its role as a potential target in advanced gastric cancer. <i>Translational Cancer Research</i> , 2020, 9, 3367-3374.	0.4	26
32	Circulating Tumor Cells are Predictive of Poor Response to Chemotherapy in Metastatic gastric cancer. <i>International Journal of Biological Markers</i> , 2015, 30, 382-386.	0.7	25
33	Triptolide as a novel agent in pancreatic cancer: the validation using patient derived pancreatic tumor cell line. <i>BMC Cancer</i> , 2018, 18, 1103.	1.1	25
34	Tumor regression grade as a clinically useful outcome predictor in patients with rectal cancer after preoperative chemoradiotherapy. <i>Surgery</i> , 2019, 165, 579-585.	1.0	25
35	CD133-positive tumor cell content is a predictor of early recurrence in colorectal cancer. <i>Journal of Gastrointestinal Oncology</i> , 2014, 5, 447-56.	0.6	25
36	Transcriptome analysis of CD133-positive stem cells and prognostic value of survivin in colorectal cancer. <i>Cancer Genomics and Proteomics</i> , 2014, 11, 259-66.	1.0	25

#	ARTICLE	IF	CITATIONS
37	Anti-tumor efficacy of fulvestrant in estrogen receptor positive gastric cancer. <i>Scientific Reports</i> , 2014, 4, 7592.	1.6	24
38	A Randomized Phase 2 Study of Neoadjuvant Chemoradiation Therapy With 5-Fluorouracil/Leucovorin or Irinotecan/S-1 in Patients With Locally Advanced Rectal Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2015, 93, 1015-1022.	0.4	24
39	A phase II study of preoperative mFOLFOX6 with short-course radiotherapy in patients with locally advanced rectal cancer and liver-only metastasis. <i>Radiotherapy and Oncology</i> , 2016, 118, 369-374.	0.3	24
40	Prospective phase II trial of everolimus in PIK3CA amplification/mutation and/or PTEN loss patients with advanced solid tumors refractory to standard therapy. <i>BMC Cancer</i> , 2017, 17, 211.	1.1	24
41	The NEXT-1 (Next generation pErsonalized tX with mulTi-omics and preclinical model) trial: prospective molecular screening trial of metastatic solid cancer patients, a feasibility analysis. <i>Oncotarget</i> , 2015, 6, 33358-33368.	0.8	24
42	MerTK is a novel therapeutic target in gastric cancer. <i>Oncotarget</i> , 2017, 8, 96656-96667.	0.8	23
43	Changes in Metabolic Syndrome Status are Associated With Altered Risk of Pancreatic Cancer: A Nationwide Cohort Study. <i>Gastroenterology</i> , 2022, 162, 509-520.e7.	0.6	23
44	Genomic Alterations in Biliary Tract Cancer Using Targeted Sequencing. <i>Translational Oncology</i> , 2016, 9, 173-178.	1.7	22
45	Phase I trial and pharmacokinetic study of tanibirumab, a fully human monoclonal antibody to vascular endothelial growth factor receptor 2, in patients with refractory solid tumors. <i>Investigational New Drugs</i> , 2017, 35, 782-790.	1.2	22
46	Two-week course of preoperative chemoradiotherapy followed by delayed surgery for rectal cancer: A phase II multi-institutional clinical trial (KROG 11-02). <i>Radiotherapy and Oncology</i> , 2014, 110, 150-154.	0.3	21
47	Direct analysis of aberrant glycosylation on haptoglobin in patients with gastric cancer. <i>Oncotarget</i> , 2017, 8, 11094-11104.	0.8	21
48	Activated cMET and IGF1R-Driven PI3K Signaling Predicts Poor Survival in Colorectal Cancers Independent of KRAS Mutational Status. <i>PLoS ONE</i> , 2014, 9, e103551.	1.1	21
49	Changes in the Mean Corpuscular Volume after Capecitabine Treatment Are Associated with Clinical Response and Survival in Patients with Advanced Gastric Cancer. <i>Cancer Research and Treatment</i> , 1970, 47, 72-77.	1.3	20
50	Disappearing or residual tiny ($\leq 5\text{mm}$) colorectal liver metastases after chemotherapy on gadoxetic acid-enhanced liver MRI and diffusion-weighted imaging: Is local treatment required?. <i>European Radiology</i> , 2017, 27, 3088-3096.	2.3	20
51	The Clinical Impact of c-MET Over-Expression in Advanced Biliary Tract Cancer (BTC). <i>Journal of Cancer</i> , 2017, 8, 1395-1399.	1.2	20
52	Clinical sequencing to assess tumor mutational burden as a useful biomarker to immunotherapy in various solid tumors. <i>Therapeutic Advances in Medical Oncology</i> , 2021, 13, 175883592199299.	1.4	20
53	The implication of FLT3 amplification for FLT targeted therapeutics in solid tumors. <i>Oncotarget</i> , 2017, 8, 3237-3245.	0.8	20
54	The impact of primary tumor location in patients with metastatic colorectal cancer: a Korean Cancer Study Group CO12-04 study. <i>Korean Journal of Internal Medicine</i> , 2019, 34, 165-177.	0.7	20

#	ARTICLE	IF	CITATIONS
55	A Retrospective Analysis for Patients with HER2-Positive Gastric Cancer Who Were Treated with Trastuzumab-Based Chemotherapy: In the Perspectives of Ethnicity and Histology. <i>Cancer Research and Treatment</i> , 2016, 48, 553-560.	1.3	19
56	The Impact of Microsatellite Instability Status and Sidedness of the Primary Tumor on the Effect of Cetuximab-Containing Chemotherapy in Patients with Metastatic Colorectal Cancer. <i>Journal of Cancer</i> , 2017, 8, 2809-2815.	1.2	18
57	Efficacy and safety of vactosertib and pembrolizumab combination in patients with previously treated microsatellite stable metastatic colorectal cancer.. <i>Journal of Clinical Oncology</i> , 2021, 39, 3573-3573.	0.8	18
58	Gemcitabine and Docetaxel Combination for Advanced Soft Tissue Sarcoma: A Nationwide Retrospective Study. <i>Cancer Research and Treatment</i> , 2018, 50, 175-182.	1.3	18
59	Tumour shrinkage at 6 weeks predicts favorable clinical outcomes in a phase III study of gemcitabine and oxaliplatin with or without erlotinib for advanced biliary tract cancer. <i>BMC Cancer</i> , 2015, 15, 530.	1.1	17
60	Genomic Profiling of Metastatic Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET) Patients in the Personalized-Medicine Era. <i>Journal of Cancer</i> , 2016, 7, 1044-1048.	1.2	17
61	Phase I Trial of Anti-MET Monoclonal Antibody in MET-Overexpressed Refractory Cancer. <i>Clinical Colorectal Cancer</i> , 2018, 17, 140-146.	1.0	17
62	The prognostic role of tumor associated glycoprotein 72 (TAG-72) in stage II and III colorectal adenocarcinoma. <i>Pathology Research and Practice</i> , 2019, 215, 171-176.	1.0	17
63	S-1 plus oxaliplatin versus capecitabine plus oxaliplatin for the first-line treatment of patients with metastatic colorectal cancer: updated results from a phase 3 trial. <i>BMC Cancer</i> , 2014, 14, 883.	1.1	16
64	Molecular Subgroup Analysis of Clinical Outcomes in a Phase 3 Study of Gemcitabine and Oxaliplatin with or without Erlotinib in Advanced Biliary Tract Cancer. <i>Translational Oncology</i> , 2015, 8, 40-46.	1.7	16
65	The Impact of Cetuximab Plus AKT- or mTOR- Inhibitor in a Patient-Derived Colon Cancer Cell Model with Wild-Type RAS and PIK3CA Mutation. <i>Journal of Cancer</i> , 2017, 8, 2713-2719.	1.2	16
66	Association of prediabetes, diabetes, and diabetes duration with biliary tract cancer risk: A nationwide cohort study. <i>Metabolism: Clinical and Experimental</i> , 2021, 123, 154848.	1.5	16
67	MerTK inhibition by RXDX-106 in MerTK activated gastric cancer cell lines. <i>Oncotarget</i> , 2017, 8, 105727-105734.	0.8	16
68	Pilot study of sirolimus in patients with PIK3CA mutant/amplified refractory solid cancer. <i>Molecular and Clinical Oncology</i> , 2017, 7, 27-31.	0.4	15
69	PIK3CA mutation detection in metastatic biliary cancer using cell-free DNA. <i>Oncotarget</i> , 2015, 6, 40026-40035.	0.8	15
70	Prospective phase II trial of pazopanib plus CapeOX (capecitabine and oxaliplatin) in previously untreated patients with advanced gastric cancer. <i>Oncotarget</i> , 2016, 7, 24088-24096.	0.8	15
71	Clinical Application of Targeted Deep Sequencing in Solid-Cancer Patients and Utility for Biomarker-Selected Clinical Trials. <i>Oncologist</i> , 2017, 22, 1169-1177.	1.9	14
72	Proton Pump Inhibitor Use and the Efficacy of Chemotherapy in Metastatic Colorectal Cancer: A Post Hoc Analysis of a Randomized Phase III Trial (AXEPT). <i>Oncologist</i> , 2021, 26, e954-e962.	1.9	14

#	ARTICLE	IF	CITATIONS
73	A nCounter CNV Assay to Detect HER2 Amplification: A Correlation Study with Immunohistochemistry and In Situ Hybridization in Advanced Gastric Cancer. <i>Molecular Diagnosis and Therapy</i> , 2016, 20, 375-383.	1.6	13
74	Everolimus for the treatment of advanced gastrointestinal or lung nonfunctional neuroendocrine tumors in East Asian patients: a subgroup analysis of the RADIANT-4 study. <i>OncoTargets and Therapy</i> , 2019, Volume 12, 1717-1728.	1.0	13
75	Clinical Outcomes of Neoadjuvant Chemotherapy in Colorectal Cancer Patients With Synchronous Resectable Liver Metastasis: A Propensity Score Matching Analysis. <i>Annals of Coloproctology</i> , 2021, 37, 244-252.	0.5	13
76	Study protocol of the Asian XELIRI Project (AXEPT): a multinational, randomized, non-inferiority, phase III trial of second-line chemotherapy for metastatic colorectal cancer, comparing the efficacy and safety of XELIRI with or without bevacizumab versus FOLFIRI with or without bevacizumab. <i>Chinese Journal of Cancer</i> , 2016, 35, 102.	4.9	12
77	Adjuvant Chemotherapy with or without Concurrent Radiotherapy for Patients with Stage IB Gastric Cancer: a Subgroup Analysis of the Adjuvant Chemoradiotherapy in Stomach Tumors (ARTIST) Phase III Trial. <i>Journal of Gastric Cancer</i> , 2018, 18, 348.	0.9	12
78	Necessity of adjuvant concurrent chemo-radiotherapy in D2-resected LN-positive gastric cancer. <i>Radiotherapy and Oncology</i> , 2018, 129, 306-312.	0.3	12
79	Molecular characterization of colorectal cancer patients and concomitant patient-derived tumor cell establishment. <i>Oncotarget</i> , 2016, 7, 19610-19619.	0.8	12
80	The efficacy of low-dose transdermal fentanyl in opioid-naïve cancer patients with moderate-to-severe pain. <i>Korean Journal of Internal Medicine</i> , 2015, 30, 88.	0.7	12
81	A Single Arm, Phase II Study of Simvastatin Plus XELOX and Bevacizumab as First-Line Chemotherapy in Metastatic Colorectal Cancer Patients. <i>Cancer Research and Treatment</i> , 2019, 51, 1128-1134.	1.3	12
82	Association between alcohol consumption and pancreatic cancer risk differs by glycaemic status: A nationwide cohort study. <i>European Journal of Cancer</i> , 2022, 163, 119-127.	1.3	12
83	Value of FGFR2 expression for advanced gastric cancer patients receiving pazopanib plus CapeOX (capecitabine and oxaliplatin). <i>Journal of Cancer Research and Clinical Oncology</i> , 2016, 142, 1231-1237.	1.2	11
84	Phase II trial of epidermal growth factor ointment for patients with Erlotinib-related skin effects. <i>Supportive Care in Cancer</i> , 2016, 24, 301-309.	1.0	11
85	The Role of Plasma Chromogranin A as Assessment of Treatment Response in Non-functioning Gastroenteropancreatic Neuroendocrine Tumors. <i>Cancer Research and Treatment</i> , 2016, 48, 153-161.	1.3	11
86	Tumor Mutational Burden as a Biomarker for Advanced Biliary Tract Cancer. <i>Technology in Cancer Research and Treatment</i> , 2021, 20, 153303382110623.	0.8	11
87	Exploratory biomarker analysis for treatment response in KRAS wild type metastatic colorectal cancer patients who received cetuximab plus irinotecan. <i>BMC Cancer</i> , 2015, 15, 747.	1.1	10
88	Regorafenib as Salvage Treatment in Korean Patients with Refractory Metastatic Colorectal Cancer. <i>Cancer Research and Treatment</i> , 2015, 47, 790-795.	1.3	10
89	Evaluation of quality of life using a tablet PC-based survey in cancer patients treated with radiotherapy: a multi-institutional prospective randomized crossover comparison of paper and tablet PC-based questionnaires (KROG 12-01). <i>Supportive Care in Cancer</i> , 2016, 24, 4399-4406.	1.0	10
90	Comprehensive molecular profiling to predict clinical outcomes in pancreatic cancer. <i>Therapeutic Advances in Medical Oncology</i> , 2021, 13, 175883592110384.	1.4	10

#	ARTICLE	IF	CITATIONS
91	Prospective phase II trial of regional hyperthermia and whole liver irradiation for numerous chemorefractory liver metastases from colorectal cancer. <i>Radiation Oncology Journal</i> , 2016, 34, 34-44.	0.7	10
92	Gastroenteropancreatic Neuroendocrine Tumors with Liver Metastases in Korea: A Clinicopathological Analysis of 72 Cases in a Single Institute. <i>Cancer Research and Treatment</i> , 2015, 47, 738-746.	1.3	10
93	Importance of the Circumferential Extent of Tumors and Clinical Lymph Node Status as Prognostic Factors after Preoperative Chemoradiotherapy and Surgery in Patients with Rectal Cancer. <i>Tumori</i> , 2010, 96, 568-576.	0.6	9
94	Clinical Significance of Mucinous Rectal Adenocarcinoma following Preoperative Chemoradiotherapy and Curative Surgery. <i>Tumori</i> , 2016, 102, 114-121.	0.6	9
95	A randomized phase II study of gemcitabine plus Z-360, a CCK2 receptor-selective antagonist, in patients with metastatic pancreatic cancer as compared with gemcitabine plus placebo. <i>Cancer Chemotherapy and Pharmacology</i> , 2017, 80, 307-315.	1.1	9
96	First-in-human phase I trial of anti-hepatocyte growth factor antibody (YYB101) in refractory solid tumor patients. <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883592092679.	1.4	9
97	A Randomized Phase II Study of Perioperative Chemotherapy Plus Bevacizumab Versus Postoperative Chemotherapy Plus Bevacizumab in Patients With Upfront Resectable Hepatic Colorectal Metastases. <i>Clinical Colorectal Cancer</i> , 2020, 19, e140-e150.	1.0	9
98	Clinical Significance of IGFBP-3 Methylation in Patients with Early Stage Gastric Cancer. <i>Translational Oncology</i> , 2015, 8, 288-294.	1.7	8
99	The Correlation Between Serum Chemokines and Clinical Outcome in Patients with Advanced Biliary Tract Cancer. <i>Translational Oncology</i> , 2018, 11, 353-357.	1.7	8
100	Combination of Docetaxel Plus Savolitinib in Refractory Cancer Patients: A Report on Phase I Trial. <i>Translational Oncology</i> , 2019, 12, 597-601.	1.7	8
101	Clinical and molecular distinctions in patients with refractory colon cancer who benefit from regorafenib treatment. <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883592096584.	1.4	8
102	Impact of <i>UGT1A1</i> genotype on the efficacy and safety of irinotecan-based chemotherapy in metastatic colorectal cancer. <i>Cancer Science</i> , 2021, 112, 4669-4678.	1.7	8
103	Molecular analysis of the randomized phase II/III study of the anti-IGF-1R antibody dalotuzumab (MK-0646) in combination with cetuximab (Cx) and irinotecan (Ir) in the treatment of chemorefractory KRAS wild-type metastatic colorectal cancer (mCRC).. <i>Journal of Clinical Oncology</i> , 2012, 30, 3531-3531.	0.8	8
104	Comparison of the 7th and the 8th AJCC Staging System for Non-metastatic D2-Resected Lymph Node-Positive Gastric Cancer Treated with Different Adjuvant Protocols. <i>Cancer Research and Treatment</i> , 2019, 51, 876-885.	1.3	8
105	Oxaliplatin/5-fluorouracil-based adjuvant chemotherapy as a standard of care for colon cancer in clinical practice: Outcomes of the ACCElox registry. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2015, 11, 334-342.	0.7	7
106	The impact of microsatellite instability status and sidedness of the primary tumor on the effect of bevacizumab-containing chemotherapy in patients with metastatic colorectal cancer. <i>Journal of Cancer</i> , 2018, 9, 1791-1796.	1.2	7
107	Prognostic Role of Carcinoembryonic Antigen Level after Preoperative Chemoradiotherapy in Patients with Rectal Cancer. <i>Journal of Gastrointestinal Surgery</i> , 2018, 22, 1772-1778.	0.9	7
108	The Impact of Primary Tumor Sidedness on the Effect of Regorafenib in Refractory Metastatic Colorectal Cancer. <i>Journal of Cancer</i> , 2019, 10, 1611-1615.	1.2	7

#	ARTICLE	IF	CITATIONS
109	Capecitabine plus Oxaliplatin as a Second-Line Therapy for Advanced Biliary Tract Cancers: A Multicenter, Open-Label, Phase II Trial. <i>Journal of Cancer</i> , 2019, 10, 6185-6190.	1.2	7
110	Detection of Fusion Genes Using a Targeted RNA Sequencing Panel in Gastrointestinal and Rare Cancers. <i>Journal of Oncology</i> , 2020, 2020, 1-8.	0.6	7
111	Incidence of FGFR2 Amplification and FGFR2 Fusion in Patients with Metastatic Cancer Using Clinical Sequencing. <i>Journal of Oncology</i> , 2022, 2022, 1-9.	0.6	7
112	Pemetrexed Monotherapy as Salvage Treatment in Patients with Metastatic Colorectal Cancer Refractory to Standard Chemotherapy: A Phase II Single-arm Prospective Trial. <i>Journal of Cancer</i> , 2018, 9, 2910-2915.	1.2	6
113	TPK1 as a predictive marker for the anti-tumour effects of simvastatin in gastric cancer. <i>Pathology Research and Practice</i> , 2020, 216, 152820.	1.0	6
114	Programmed Death Ligand 1 Expression as a Prognostic Marker in Patients with Advanced Biliary Tract Cancer. <i>Oncology</i> , 2021, 99, 365-372.	0.9	6
115	Prognostic significance of survivin in rectal cancer patients treated with surgery and postoperative concurrent chemo-radiation therapy. <i>Oncotarget</i> , 2016, 7, 62676-62686.	0.8	6
116	Can we omit prophylactic inguinal nodal irradiation in anal cancer patients?. <i>Radiation Oncology Journal</i> , 2015, 33, 83.	0.7	6
117	HER2 Aberrations as a Novel Marker in Advanced Biliary Tract Cancer. <i>Frontiers in Oncology</i> , 2022, 12, 834104.	1.3	6
118	Oxaliplatin (3 months <i>v</i> 6 months) With 6 Months of Fluoropyrimidine as Adjuvant Therapy in Patients With Stage II/III Colon Cancer: KCSG CO09-07. <i>Journal of Clinical Oncology</i> , 2022, 40, 3868-3877.	0.8	6
119	Immunohistochemical Detection of p53 Expression in Patients with Preoperative Chemoradiation for Rectal Cancer: Association with Prognosis. <i>Yonsei Medical Journal</i> , 2015, 56, 82.	0.9	5
120	Efficacy and Safety of FOLFIRI Regimen in Elderly Versus Nonelderly Patients with Metastatic Colorectal or Gastric Cancer. <i>Oncologist</i> , 2017, 22, 293-303.	1.9	5
121	Antitumor activity of sorafenib plus CDK4/6 inhibitor in pancreatic patient derived cell with KRAS mutation. <i>Journal of Cancer</i> , 2018, 9, 3394-3399.	1.2	5
122	The impact of primary tumor site on outcomes of treatment with etoposide and cisplatin in grade 3 gastroenteropancreatic neuroendocrine carcinoma. <i>Journal of Cancer</i> , 2019, 10, 3140-3144.	1.2	5
123	Systematic Evaluation of Gastric Tumor Cell Index and Two-Drug Combination Therapy via 3-Dimensional High-Throughput Drug Screening. <i>Frontiers in Oncology</i> , 2019, 9, 1327.	1.3	5
124	Use of Gefitinib in EGFR-Amplified Refractory Solid Tumors: An Open-Label, Single-Arm, Single-Center Prospective Pilot Study. <i>Targeted Oncology</i> , 2020, 15, 185-192.	1.7	5
125	The prevalence of homologous recombination deficiency (HRD) in various solid tumors and the role of HRD as a single biomarker to immune checkpoint inhibitors. <i>Journal of Cancer Research and Clinical Oncology</i> , 2022, 148, 2427-2435.	1.2	5
126	The impact of pathologic differentiation (well/poorly) and the degree of Ki-67 index in patients with metastatic WHO grade 3 GEP-NECs. <i>Oncotarget</i> , 2017, 8, 73974-73980.	0.8	5

#	ARTICLE	IF	CITATIONS
127	Effect of leukocyte alteration on treatment outcomes following preoperative chemoradiotherapy in patients with rectal cancer. <i>Radiation Oncology Journal</i> , 2017, 35, 217-226.	0.7	5
128	Carcinoembryonic Antigen Improves the Performance of Magnetic Resonance Imaging in the Prediction of Pathologic Response after Neoadjuvant Chemoradiation for Patients with Rectal Cancer. <i>Cancer Research and Treatment</i> , 2020, 52, 446-454.	1.3	5
129	The use of regorafenib for patients with refractory metastatic colorectal cancer in clinical practice. <i>OncoTargets and Therapy</i> , 2019, Volume 12, 225-231.	1.0	4
130	Prognostic Factors of Survival with Aflibercept and FOLFIRI (fluorouracil, leucovorin, irinotecan) as Second-line Therapy for Patients with Metastatic Colorectal Cancer. <i>Journal of Cancer</i> , 2021, 12, 460-466.	1.2	4
131	Neutralizing antibody to FGFR2 can act as a selective biomarker and potential therapeutic agent for gastric cancer with FGFR2 amplification. <i>American Journal of Translational Research (discontinued)</i> , 2019, 11, 4508-4515.	0.0	4
132	Whole-Genome and Transcriptome Sequencing Identified NOTCH2 and HES1 as Potential Markers of Response to Imatinib in Desmoid Tumor (Aggressive Fibromatosis): A Phase II Trial Study. <i>Cancer Research and Treatment</i> , 2022, 54, 1240-1255.	1.3	4
133	Novel TGF- β 2 signatures in metastatic colorectal cancer patients treated with vactosertib in combination with pembrolizumab. , 2020, , .		3
134	Phase Ib dose-escalation study of Pexa-Vec (pexastimogene devacirepvec; JX-594), an oncolytic and immunotherapeutic vaccinia virus, administered by intravenous (IV) infusions in patients with metastatic colorectal carcinoma (mCRC).. <i>Journal of Clinical Oncology</i> , 2013, 31, 3608-3608.	0.8	3
135	Prognostic and predictive value of liver volume in colorectal cancer patients with unresectable liver metastases. <i>Radiation Oncology Journal</i> , 2014, 32, 77.	0.7	3
136	Placebo-controlled, double-blinded multi-center phase III trial of XELIRI/FOLFIRI plus simvastatin in metastatic colorectal cancer.. <i>Journal of Clinical Oncology</i> , 2015, 33, 3576-3576.	0.8	3
137	Light-to-Moderate Alcohol Consumption Increases the Risk of Biliary Tract Cancer in Prediabetes and Diabetes, but Not in Normoglycemic Status: A Nationwide Cohort Study. <i>Journal of Clinical Oncology</i> , 2022, 40, 3623-3632.	0.8	3
138	Selective colony area method for heterogeneous patient-derived tumor cell lines in anti-cancer drug screening system. <i>PLoS ONE</i> , 2019, 14, e0215080.	1.1	2
139	Phase I clinical trial of KML001 monotherapy in patients with advanced solid tumors. <i>Expert Opinion on Investigational Drugs</i> , 2020, 29, 1059-1067.	1.9	2
140	Phase I trial and pharmacokinetic study of Tanibirumab, a fully human monoclonal antibody to the vascular endothelial growth factor receptor 2 in patients with refractory solid tumors.. <i>Journal of Clinical Oncology</i> , 2015, 33, 2522-2522.	0.8	2
141	Nintedanib (N) plus best supportive care (BSC) versus placebo plus BSC for the treatment of patients (pts) with metastatic colorectal cancer (mCRC) refractory to standard therapies: Health-related quality of life (HRQoL) results of the Phase III LUME-Colon 1 study.. <i>Journal of Clinical Oncology</i> , 2017, 35, 671-671.	0.8	2
142	First-in-human phase I trial of anti-hepatocyte growth factor (HGF) antibody (YYB101) in refractory solid tumor patients: Integrative pathologic-genomic analysis and the final results.. <i>Journal of Clinical Oncology</i> , 2019, 37, 3104-3104.	0.8	2
143	Prospective phase II trial of pazopanib plus CapeOX (capecitabine and oxaliplatin) in previously untreated patients with advanced gastric cancer.. <i>Journal of Clinical Oncology</i> , 2015, 33, 4049-4049.	0.8	2
144	Tumor microenvironment based on PD-L1 and CD8 T-cell infiltration correlated with the response of MSS mCRC patients treated vactosertib in combination with pembrolizumab. , 2021, 9, A82-A82.		2

#	ARTICLE	IF	CITATIONS
145	Phase 1b study of vactosertib in combination with nab-IRI plus 5FU/LV in patients with metastatic pancreatic ductal adenocarcinoma who have failed first-line gemcitabine/nab-paclitaxel.. Journal of Clinical Oncology, 2022, 40, TPS632-TPS632.	0.8	2
146	Adjuvant chemoradiation with 5-fluorouracil/leucovorin versus S-1 in gastric cancer patients following D2 lymph node dissection surgery: a feasibility study. Anticancer Research, 2014, 34, 6585-91.	0.5	2
147	To Excavate Biomarkers Predictive of the Response for Capecitabine plus RAD001 through Nanostring-Based Multigene Assay in Advanced Gastric Cancer Patients. Journal of Cancer, 2016, 7, 2173-2178.	1.2	1
148	Clinical Outcomes of Salvage Chemoradiotherapy for Locally Recurrent Biliary Tract Cancer. Tumori, 2017, 103, 345-352.	0.6	1
149	Pemetrexed/Erlotinib as a Salvage Treatment in Patients with High EGFR-Expressing Metastatic Colorectal Cancer Following Failure of Standard Chemotherapy: A Phase II Single-Arm Prospective Study. Targeted Oncology, 2020, 15, 67-73.	1.7	1
150	A phase 1 dose-escalation and dose-expansion study to assess the safety and efficacy of CKD-516, a novel vascular disrupting agent, in combination with Irinotecan in patients with previously treated metastatic colorectal cancer. Investigational New Drugs, 2021, 39, 1335-1347.	1.2	1
151	ATM Expression as a Prognostic Marker in Patients With Advanced Biliary Tract Cancer Treated With First-line Gemcitabine and Platinum Chemotherapy. In Vivo, 2021, 35, 499-505.	0.6	1
152	A randomized phase II study of neoadjuvant chemoradiotherapy with 5-FU/leucovorin or irinotecan/S1 in patients with locally advanced rectal cancer.. Journal of Clinical Oncology, 2013, 31, 511-511.	0.8	1
153	Interim safety analysis from a randomized, open-label, multicenter, phase III trial of capecitabine plus oxaliplatin (XELOX) versus capecitabine (X) as first-line chemotherapy in elderly patients with advanced gastric cancer (AGC).. Journal of Clinical Oncology, 2014, 32, 158-158.	0.8	1
154	Phase II XELOX + lapatinib treatment in HER2-amplified gastric cancer: Monitoring with serial cell-free DNA genomics.. Journal of Clinical Oncology, 2017, 35, e15610-e15610.	0.8	1
155	First-in-human phase I trial of anti-hepatocyte growth factor (HGF) antibody (YYB101) in refractory solid tumor patients.. Journal of Clinical Oncology, 2018, 36, e14501-e14501.	0.8	1
156	A prospective multicenter phase II study of sunitinib in patients with advanced aggressive fibromatosis.. Journal of Clinical Oncology, 2013, 31, 10589-10589.	0.8	1
157	Determining Which Patients Require Preoperative Pelvic Radiotherapy Before Curative-Intent Surgery and/or Ablation for Metastatic Rectal Cancer. Annals of Surgical Oncology, 2022, , 1.	0.7	1
158	Phase 1b study of vactosertib in combination with oxaliplatin with 5FU/LV (FOLFOX) in patients with metastatic pancreatic cancer who have failed first-line gemcitabine/nab-paclitaxel.. Journal of Clinical Oncology, 2022, 40, e16299-e16299.	0.8	1
159	A phase I study of IMC-001, a PD-L1 blocker, in patients with metastatic or locally advanced solid tumors. Investigational New Drugs, 2021, 39, 1624-1632.	1.2	0
160	SSTR2A Protein Expression in Neuroendocrine Neoplasms of the Colorectum. Korean Journal of Pathology, 2011, 45, 276.	1.2	0
161	Perceptions of clinical trials in gastrointestinal/hepatobiliary cancer patients: A comprehensive survey in a Korean tertiary hospital.. Journal of Clinical Oncology, 2012, 30, e13094-e13094.	0.8	0
162	A phase Ib dose escalation study of JX-594 (TK-vaccinia virus expressing GM-CSF) administered by biweekly intravenous infusion in patients with metastatic, refractory colorectal carcinoma.. Journal of Clinical Oncology, 2012, 30, e13044-e13044.	0.8	0

#	ARTICLE	IF	CITATIONS
163	A prospective phase II study of neoadjuvant FOLFOX6 plus cetuximab in patients with colorectal cancer and unresectable liver metastasis.. Journal of Clinical Oncology, 2012, 30, e14072-e14072.	0.8	0
164	Open-label, phase IIIb, multicenter, expanded access study of everolimus in patients with advanced neuroendocrine tumors (NET).. Journal of Clinical Oncology, 2013, 31, 4138-4138.	0.8	0
165	Pathway redundancy and feedback loop as drivers of nonresponse in colorectal cancer treatments.. Journal of Clinical Oncology, 2013, 31, e14626-e14626.	0.8	0
166	Global clinical experience with adjuvant oxaliplatin/5-fluorouracil (5-FU)-based chemotherapy for colon cancer: Outcomes of the ACCElox registry.. Journal of Clinical Oncology, 2013, 31, e14624-e14624.	0.8	0
167	Molecular profiling of patient derived cells (PDCs) from metastatic cancer patients using CancerSCAN: Highly profiled models to test the efficacy of genome-directed therapy in cancer.. Journal of Clinical Oncology, 2015, 33, e22241-e22241.	0.8	0
168	Longitudinal follow-up of quality of life in gastrointestinal cancer patients after curative surgery in South Korea.. Journal of Clinical Oncology, 2016, 34, 697-697.	0.8	0
169	The clinicopathologic features and treatment of 607 hindgut neuroendocrine tumor (NET) patients at a single institution.. Journal of Clinical Oncology, 2016, 34, 4091-4091.	0.8	0
170	The impact of cetuximab plus AKT- or mTOR- inhibitor in patient-derived colon cancer cell model with RAS wild type and PIK3CA mutation.. Journal of Clinical Oncology, 2016, 34, e15153-e15153.	0.8	0
171	Programmed death (PD)-ligand 1 (L1) expression and mismatch repair (MMR) deficiency across tumor types: Candidates for checkpoint inhibitor based immunotherapy.. Journal of Clinical Oncology, 2017, 35, e14622-e14622.	0.8	0
172	The impact of pathologic differentiation (well/ poorly) and the degree of Ki-67 index in patients with metastatic WHO grade 3 GEP-NECs.. Journal of Clinical Oncology, 2017, 35, e15686-e15686.	0.8	0
173	VariantPlex panel to detect genomic aberrations in oncology patients with rare cancer type.. Journal of Clinical Oncology, 2018, 36, e24234-e24234.	0.8	0
174	Detection of targetable fusions using FusionPlex in oncology patients.. Journal of Clinical Oncology, 2018, 36, e24238-e24238.	0.8	0
175	Impact of the prior chemotherapy with two different fluoropyrimidines on the efficacy of CapelRI or FOLFIRI in metastatic colorectal cancer: An exploratory analysis of the phase III AXEPT trial.. Journal of Clinical Oncology, 2019, 37, 711-711.	0.8	0
176	Detection of circulating tumor cells (CTCs) in cerebrospinal fluid of a patient with HER2-overexpressing gastric cancer and single cell analysis of intra-patient heterogeneity of CTCs. Translational Cancer Research, 2019, 8, 2107-2112.	0.4	0
177	A clinical scoring system for survival prediction in advanced gastric cancer.. Journal of Clinical Oncology, 2020, 38, 436-436.	0.8	0
178	Pemetrexed plus erlotinib as a salvage treatment in high EGFR-expressing metastatic colorectal cancer patients following failure of standard chemotherapy: A phase II single-arm prospective study.. Journal of Clinical Oncology, 2020, 38, 104-104.	0.8	0
179	823â€¦Spatial analysis of tumor-infiltrating lymphocytes correlates with the response of metastatic colorectal cancer patients treated with vactosertib in combination with pembrolizumab. , 2021, 9, A861-A861.		0
180	Safety and effectiveness of aflibercept in combination with FOLFIRI in Korean patients with metastatic colorectal cancer who received oxaliplatin-containing regimen. Journal of Cancer Research and Clinical Oncology, 2022, , 1.	1.2	0

#	ARTICLE	IF	CITATIONS
181	ASO Visual Abstract: Determining Which Patients Require Preoperative Pelvic Radiotherapy Before Curative Intent Surgery and/or Ablation for Metastatic Rectal Cancer. <i>Annals of Surgical Oncology</i> , 2022, , .	0.7	0